[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100488676":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":29,"responsibleParty":45,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":19,"enrollmentInfo":57,"targetDuration":19,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":19,"overallStatus":31,"whyStopped":19,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Maria Cecilia Hospital","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"consecutive patients","20 patients clinically indicated for a endo-epicardial catheter-based mapping procedure for the treatment of ventricular tachycardia\u002F ventricular fibrillation substrate",[12],"Procedure: ablation",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"PROCEDURE","ablation","epicardial substrate homogenization (ablating abnormal fragmented prolonged low-frequency ventricular electrograms) in consecutive patients undergoing catheter ablation",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Saverio Iacopino, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":19,"email":28},"CONTACT","0545.217228","siacopino@gvmnet.it",[30],{"facility":5,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"RECRUITING","Cotignola","Ravenna","48033","Italy","IT",{"type":38,"coordinates":39},"Point",[40,41],11.93852,44.38572,{"lat":41,"lon":40},[44],{"name":22,"role":26,"phone":19,"phoneExt":19,"email":19},{"type":46,"investigatorFullName":19,"investigatorTitle":19,"investigatorAffiliation":19,"oldNameTitle":19,"oldOrganization":19},"SPONSOR","100488676","brugada-syndrome-substrate-characterization-and-ablation-100488676",false,"NCT05643209","Brugada Syndrome Substrate Characterization and Ablation","Brugada Syndrome Substrate Characterization and Ablation: Insights From ECG BrS Type I Pattern, Novel Prognostic Index dST-Tiso and High Density Mapping","UNCOVERBrS","Inclusion Criteria:\n\n1. Symptomatic patients diagnosed with BrS-ECG pattern of types 1 and 2, both spontaneous and arising after Ajmaline tests, already implanted with an ICD.\n\n   Symptomatic patients are defined as those who present ≥1 documented episode of VT \u002F VF in the 12 months prior to enrollment.\n2. Patients eligible for ablation with 3D high-density mapping system in accordance with national guidelines, IFU and according to medical decision;\n3. Adult patients able to provide written informed consent\n\nExclusion Criteria:\n\n1. Patients unable to provide written informed consent;\n2. Patients unable to guarantee their presence at future FU visits;\n3. Patients who, according to medical judgment, have a life expectancy of less than 12 months;\n4. Patients who have undergone cardiac ablation in the 90 days prior to enrollment.\n5. Patients who have had adverse events that have not been resolved after any invasive procedure;\n6. Women potentially pregnant or planning to become pregnant.","ALL","18 Years",{"count":58,"type":59},20,"ESTIMATED","INTERVENTIONAL",[62],"NA","Independent, single center, prospective study, to evaluate the efficacy, in consecutive BrS patients undergoing catheter ablation, at medium-long term follow-up after epicardial substrate homogenization. The target area is defined collecting signals using high density and high resolution mapping with equi-spaced electrode array. The ablation of abnormal fragmented prolonged low-frequency ventricular electrograms is performed by contact force catheter.",[65],"Brugada Syndrome","2025-08-12",{"date":68,"type":69},"2025-08-15","ACTUAL",{"date":71,"type":69},"2023-02-01",{"date":73,"type":59},"2026-06-30",{"name":5,"class":6},1]